Company news

Phathom Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

October 26, 2024

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

August 18, 2024

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

July 29, 2024

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

July 28, 2024

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

July 17, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

May 14, 2024

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

April 28, 2024

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

March 25, 2024

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 6, 2024

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

February 28, 2024

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

February 12, 2024

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 30, 2024

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

December 13, 2023

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

December 5, 2023

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

November 27, 2023

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

November 8, 2023

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

October 31, 2023

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

October 29, 2023

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

September 25, 2023

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

August 20, 2023

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

August 9, 2023

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

June 11, 2023

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

June 8, 2023

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

May 22, 2023

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

May 22, 2023

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

May 22, 2023

Phathom Pharmaceuticals Reports First Quarter 2023 Results

May 9, 2023

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

May 8, 2023

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

April 3, 2023

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Phathom Pharmaceuticals Provides Regulatory Updates

February 8, 2023

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

January 7, 2023

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

January 2, 2023

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 7, 2022

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

November 2, 2022

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

October 31, 2022

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

October 23, 2022

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

October 22, 2022

Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

October 17, 2022

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

September 25, 2022

Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 1, 2022

Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

May 31, 2022

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

May 24, 2022

Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

May 23, 2022

Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

May 16, 2022

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

May 9, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.